NDC product
OPDIVO QVANTIG
NDC 0003-3120 · E.R. Squibb & Sons, L.L.C.
Key facts
| Product NDC | 0003-3120 |
|---|---|
| Proprietary name | OPDIVO QVANTIG |
| Nonproprietary name | nivolumab and hyaluronidase-nvhy |
| Substances | NIVOLUMAB, HYALURONIDASE (HUMAN RECOMBINANT) |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | E.R. Squibb & Sons, L.L.C. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761381 |
| Pharmacologic classes | Endoglycosidase [EPC], Glycoside Hydrolases [CS], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
| Marketing start | Dec 27, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: